Treatments

Monoclonal antibodies remain top option for COVID-19 treatment, but studies reveal a potential alternative

Lung Airway Chip could transform cystic fibrosis research, potentially leading to better treatments and outcomes

The paper builds on another recent study the RIT-Cornell team published in Soft Matter

In a trial, Paxlovid reduced COVID-19 related hospitalization or death by 88 percent

Research from this past year highlights the potential of CRISPR-Cas9 technology in modeling and treating rare disease

Patients with acute respiratory failure may now enroll in NIH-sponsored coronavirus treatment trial

Research shows that the drug clofazimine is a potent antiviral against SARS-CoV-2 and prevents cytokine storm

If approved for use, it would be the first drug to delay or prevent Type 1 diabetes

Novel, plasmid-free manufacturing system reduces cost of goods and improves AAV quality to enable development of safer gene therapies

Longitudinal study of COVID-19 convalescent plasma donors sheds light on ideal timing to donate